CoChat

Neutralization of IL‐17 rescues amyloid‐β‐induced neuroinflammation and memory impairment

Open access
Cristiano, Claudia, Volpicelli, Floriana, Lippiello, Pellegrino, Buono, Benedetta, Raucci, Federica, Piccolo, Marialuisa, Iqbal, Asif Jilani, Irace, Carlo, Miniaci, Maria Concetta, Perrone Capano, Carla, Calignano, Antonio, Mascolo, Nicola, Maione, Francesco · 2019 · British Journal of Pharmacology
Cited by 141

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Background and purpose: Alzheimer's disease (AD) is a common neurodegenerative disease characterized by a neuroinflammatory state, and to date, there is no cure and its treatment represents a large unmet clinical need. The involvement of Th17 cells in the pathogenesis of AD‐related neuroinflammation has been reported in several studies. However, the role of the cytokine, IL‐17 has not been well addressed. Herein, we investigate the effects of IL‐17 neutralizing antibody (IL‐17Ab) injected by i.c.v. or intranasal (IN) routes on amyloid‐β (Aβ)‐induced neuroinflammation and memory impairment in mice. Experimental approach: Aβ 1–42 was injected into cerebral ventricles of adult CD1 mice. These mice received IL‐17Ab via i.c.v. either at 1 h prior to Aβ 1–42 injection or IN 5 and 12 days after Aβ 1–42 injection. After 7 and 14 days of Aβ 1–42 administration, we evaluated olfactory, spatial and working memory and performed biochemical analyses on whole brain and specific brain areas. Key results: Pretreatment with IL‐17Ab, given, i.c.v., markedly reduced Aβ 1–42‐induced neurodegeneration, improved memory function, and prevented the increase of pro‐inflammatory mediators in a dose‐dependent manner at 7 and 14 days. Similarly, the double IN administration of IL‐17Ab after Aβ 1–42 injection reduced neurodegeneration, memory decline, and the levels of proinflammatory mediators and cytokines. Conclusion and implications: These findings suggest that the IL‐17Ab reduced neuroinflammation and behavioural symptoms induced by Aβ. The efficacy of IL‐17Ab IN administration in reducing Aβ 1–42 neurodegeneration points to a possible future therapeutic approach in patients with AD. Linked Articles: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.14586

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 141

Metadata

Authors
Cristiano, C., Volpicelli, F., Lippiello, P., Buono, B., Raucci, F., Piccolo, M., Iqbal, A. J., Irace, C., Miniaci, M. C., Perrone Capano, C., Calignano, A., Mascolo, N., & Maione, F.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2019-03-03
Volume
176
Issue
18
Pages
3544-3557
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2912374833
Cited by
141
References
16
FWCI
9.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neutralization of IL‐17 rescues amyloid‐β‐induced neuroinflammation and memory impairment. https://app.cochat.ai/papers/10.1111/bph.14586
The paper
Cristiano, C., Volpicelli, F., Lippiello, P., Buono, B., Raucci, F., Piccolo, M., Iqbal, A. J., Irace, C., Miniaci, M. C., Perrone Capano, C., Calignano, A., Mascolo, N., & Maione, F. (2019). Neutralization of IL‐17 rescues amyloid‐β‐induced neuroinflammation and memory impairment. British Journal of Pharmacology. https://doi.org/10.1111/bph.14586

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.